Sharip, M.T.; Nishad, N.; Pillay, L.; Goordyal, N.; Goerge, S.; Subramanian, S.
Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn’s Disease: A Review of Comparative Effectiveness Studies. J. Clin. Med. 2024, 13, 2187.
https://doi.org/10.3390/jcm13082187
AMA Style
Sharip MT, Nishad N, Pillay L, Goordyal N, Goerge S, Subramanian S.
Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn’s Disease: A Review of Comparative Effectiveness Studies. Journal of Clinical Medicine. 2024; 13(8):2187.
https://doi.org/10.3390/jcm13082187
Chicago/Turabian Style
Sharip, Mohmmed Tauseef, Nilanga Nishad, Lushen Pillay, Nilkantsingh Goordyal, Samuel Goerge, and Sreedhar Subramanian.
2024. "Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn’s Disease: A Review of Comparative Effectiveness Studies" Journal of Clinical Medicine 13, no. 8: 2187.
https://doi.org/10.3390/jcm13082187
APA Style
Sharip, M. T., Nishad, N., Pillay, L., Goordyal, N., Goerge, S., & Subramanian, S.
(2024). Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn’s Disease: A Review of Comparative Effectiveness Studies. Journal of Clinical Medicine, 13(8), 2187.
https://doi.org/10.3390/jcm13082187